Day One Biopharmaceuticals pany(DAWN) - 2025 Q2 - Quarterly Results

Exhibit 99.1 Day One Reports Second Quarter 2025 Financial Results and Corporate Progress OJEMDA TM (tovorafenib) net product revenue of $33.6 million in Q2 2025, a 10% quarter-over-quarter increase OJEMDA full-year 2025 net product revenue expected to be $140 to $150 million Ended the second quarter with $453.1 million in cash, cash equivalents and short-term investments Company to host conference call and webcast today, August 5, 4:30 p.m. ET BRISBANE, Calif., August 5, 2025 – Day One Biopharmaceuticals, ...